The role of prophylaxis in the management of von Willebrand disease: today and tomorrow

Thrombosis Research

Volumn 124, Issue SUPPL. 1, 2009, Pages

  Abshire, Thomas ^a  

^a EMORY UNIVERSITY   (United States)

Author keywords

Factor VIII; Prophylaxis; Von Willebrand disease; Von Willebrand factor

Indexed keywords

BLOOD CLOTTING FACTOR 8; DESMOPRESSIN; VON WILLEBRAND FACTOR;

ANEMIA; ANGIODYSPLASIA; ARTHROPATHY; ARTICLE; BLEEDING; CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE SEVERITY; EPISTAXIS; GASTROINTESTINAL HEMORRHAGE; HEALTH; HEMARTHROSIS; HEMOPHILIA; HUMAN; MENORRHAGIA; ORAL BLEEDING; PRIORITY JOURNAL; PROPHYLAXIS; QUALITY OF LIFE; RECURRENT DISEASE; RISK ASSESSMENT; THROMBOSIS; TREATMENT INDICATION; VON WILLEBRAND DISEASE;

ANEMIA; COAGULANTS; GASTROINTESTINAL DISEASES; HUMANS; PHYSICIAN'S PRACTICE PATTERNS; VON WILLEBRAND DISEASES; VON WILLEBRAND FACTOR;

EID: 71549147817     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(09)70153-7     Document Type: Article

References (31)

1. Berntorp E., and Petrini P. Long-term prophylaxis in von Willebrand disease. Blood Coagul Fibrinolysis 16 Suppl 1 (2005) S23-S26
2. Lak M., Peyvandi F., and Mannucci P.M. Clinical manifestations and complications of childbirth and replacement therapy in 385 Iranian patients with type 3 von Willebrand disease. Br J Haematol 111 (2000) 1236-1239
3. Federici A.B. Prophylaxis of bleeding episodes in patients with von Willebrand's disease. Blood Transfus 6 Suppl 2 (2008) s26-s32
4. Berntorp E. Prophylaxis in von Willebrand disease. Haemophilia 14 Suppl 5 (2008) 47-53
5. Lillicrap D., Poon M.C., Walker I., Xie F., and Schwartz B.A. Efficacy and safety of the factor VIII/von Willebrand factor concentrate Haemate P/Humate-P: ristocetin cofactor unit dosing in patients with von Willebrand disease. Thromb Haemost 87 (2002) 224-230
6. Franchini M., Rossetti G., Tagliaferri A., Pattacini C., Pozzoli D., Lippi G., et al. Efficacy and safety of factor VIII/von Willebrand factor concentrate (Haemate P®) preventing bleeding during surgery or invasive procedures in patients with von Willebrand's disease. Haematologica 88 (2003) 1279-1283
7. Thompson A.R., Gill J.C., Ewenstein B.M., Mueller-Velten G., and Schwartz B.A. Successful treatment for patients with von Willebrand disease undergoing urgent surgery using factor VIII/VWF concentrate (Humate-P®). Haemophilia 10 (2004) 42-51
8. Federici A.B., Castaman G., Franchini M., Morfini M., Zanon E., Coppola A., et al. Clinical use of Haemate® P in inherited von Willebrand's disease: a cohort study on 100 Italian patients. Haematologica 92 (2007) 944-951
9. Lethagen S., Kyrle P.A., Castaman G., Haertel S., and Mannucci M. Von Willebrand factor/factor VIII concentrate (Haemate P®) dosing based on pharmacokinetics: a prospective multicenter trial in elective surgery. J Thromb Haemost 5 (2007) 1420-1430
10. Federici A.B., Gianniello F., and Mannucci P.M. Secondary long-term prophylaxis in von Willebrand disease: an Italian cohort study. Haematologica Rep 1 (2005) 15-20
11. Lethagen S. Clinical experience of prophylactic treatment in von Willebrand disease. Thromb Res 118 Suppl 1 (2006) S9-11
12. Mannucci P.M. Prophylaxis in congenital coagulation disorders: past, present and future. Blood Transfus 6 Suppl 2 (2008) s1-s3
13. Manco-Johnson M.J., Abshire T.C., Shapiro A.D., Riske B., Hacker M.R., Kilcoyne R., et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe haemophilia. N Engl J Med 357 (2007) 535-544
14. Berntorp E., Astermark J., Björkman S., Blanchette V.S., Fischer K., Giangrande P.L., et al. Consensus perspectives on prophylactic therapy for haemophilia: summary statement. Haemophilia 9 Suppl 1 (2003) 1-4
15. Berntorp E., Abshire T., and for the von Willebrand Disease Prophylaxis Network Steering Committee. The von Willebrand disease prophylaxis network: exploring a treatment concept. J Thromb Haemost 4 (2006) 2511-2512
16. Roosendaal G., Vianen M.E., Wenting M.J.G., van Rinsum A.C., van den Berg H.M., Lafeber F.P.J.G., et al. Iron deposits and catabolic properties of synovial tissue from patients with haemophilia. J Bone Joint Surg Br 80 (1998) 540-545
17. Wen F.-Q., Jabbar A.A., Chen Y.-X., Kazarian T., Patel D.A., and Valentino L.A. c-myc protooncogene expression in haemophilic synovitis: in vitro studies of the effects of iron and ceramide. Blood 100 (2002) 912-916
18. Hakobyan N., Kazarian T., Jabbar A.A., Jabbar K.J., and Valentino L.A. Pathobiology of hemophilic synovitis I: overexpression of mdm2 oncogene. Blood 104 (2004) 2060-2064
19. Aledort L.M., Haschmeyer R.H., and Pettersson H. A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs. The Orthopaedic Outcome Study Group. J Intern Med 236 (1994) 391-399
20. Abshire T.C. Prophylaxis and von Willebrand disease (vWD). Thromb Res 118 Suppl 1 (2006) S3-S7
21. Petrini P., Berntorp E., and Stigendal L. Long-term prophylaxis in von Willebrand disease. Experience from Sweden. Haematologica Rep 1 (2005) 30-31
22. Centers for Disease Control and Prevention. The Universal Data Collection Project; surveillance update 2005. Available at: http://www.cdc.gov/ncbddd/hbd/surveillance.htm#UDC
23. Centers for Disease Control and Prevention. The Universal Data Collection Program. Summary report of UDC activity national; treatment and outcome by severity (vWD & other), updated March 24, 2009. Available at: http://www.cdc.gov/ncbddd/hbd/surveillance.htm#UDC last accessed August 21, 2009.
24. Makris M. Gastrointestinal bleeding in von Willebrand disease. Thromb Res 118 Suppl 1 (2006) S13-S17
25. Fressinaud E., and Meyer D. International survey of patients with von Willebrand disease and angiodysplasia. Thromb Haemost 70 (1993) 546
26. Kern M., Blanchette V., Sain A.M., Einarson T.R., and Feldman B.M. Clinical and cost implications of target joints in Canadian boys with severe hemophilia A. J Pediatr 145 (2004) 628-634
27. Risebrough N., Oh P., Blanchette V., Curtin J., Hitzler J., and Feldman B.M. Cost-utility analysis of Canadian tailored prophylaxis, primary prophylaxis and on-demand therapy in young children with severe haemophilia A. Haemophilia 14 (2008) 743-752
28. Abshire T. An approach to target joint bleeding in hemophilia: prophylaxis for all or individualized treatment?. J Pediatr 145 (2004) 581-583
29. Gröner A. Pathogen safety of plasma-derived products - Haemate® P/Humate-P®. Haemophilia 14 Suppl 5 (2008) 54-71
30. Mannucci P.M. Venous thromboembolism in von Willebrand disease. Thromb Haemost 88 (2002) 378-379
31. Makris M., Colvin B., Gupta V., Shields M.L., and Smith M.P. Venous thrombosis following the use of intermediate purity FVIII concentrate to treat patients with von Willebrand's disease. Thromb Haemost 88 (2002) 387-388